Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2014:2014:245247.
doi: 10.1155/2014/245247. Epub 2014 Jun 23.

Changes in osteoblastic activity in patient who received bortezomib as second line treatment for plasma cell myeloma: a prospective multicenter study

Ki-Seong Eom  1 , Seok Jin Kim  2 , Je-Jung Lee  3 , Cheolwon Suh  4 , Jin Seok Kim  5 , Sung-Soo Yoon  6 , Byung Soo Kim  7 , Hye Jin Kang  8 , Young Jin Choi  9 , Chul Soo Kim  10 , Yang Soo Kim  11 , Jae-Yong Kwak  12 , Yoo Jin Kim  1 , Young Don Joo  13 , Yeung-Chul Mun  14 , Deog Yeon Jo  15 , Joon Seong Park  16 , Chi-Young Park  17 , Sung-Hyun Kim  18 , Chang-Ki Min  1
Affiliations
Clinical Trial

Changes in osteoblastic activity in patient who received bortezomib as second line treatment for plasma cell myeloma: a prospective multicenter study

Ki-Seong Eom et al. Biomed Res Int. 2014.

Abstract

We conducted a prospective multicenter study identifying the role of bortezomib in patients with relapsed or refractory plasma cell myeloma (PCM) in bone resorption and formation via bone turnover markers. A total of 104 patients received at least 1 cycle of bortezomib. Most of them had advanced disease (n = 89). Among them, 75 patients completed 4 cycles of treatment. Most of the patients (81.7%) were treated in combination with steroid. After the 4th cycle treatment, 47 of 75 patients achieved CR, nCR, VGPR, and PR (64.4%), while 26 patients achieved less than PR (35.6%). The proportion of patients who achieved ≥ PR increased as patients received more treatment cycles, reaching 90% after the 8th cycle. DKK-1 levels decreased significantly posttreatment. Bone formation markers (bALP and OC) and osteoclast regulator such as sRANKL also decreased significantly. These findings were observed primarily in patients who received steroid and who had a longer disease duration. While sRANKL demonstrated significant reduction posttreatment, osteoprotegerin (OPG) level did not significantly change posttreatment, resulting in a decreased sRANKL/OPG ratio (P = 0.037). In conclusion, our clinical data suggest that treatment with bortezomib and steroid may rearrange the metabolic balance between osteoblast and osteoclast activities in PCM.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Response to bortezomib treatment.
Figure 2
Figure 2
Peripheral neuropathy according to bortezomib treatment cycles.
See this image and copyright information in PMC

References

    1. Terpos E, Sezer O, Croucher P, Dimopoulos M. Myeloma bone disease and proteasome inhibition therapies. Blood. 2007;110(4):1098–1104. - PubMed
    1. Terpos E, Sezer O, Croucher PI, et al. The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. Annals of Oncology. 2009;20(8):1303–1317. - PubMed
    1. Berenson JR, Lichtenstein A, Porter L, et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Journal of Clinical Oncology. 1998;16(2):593–602. - PubMed
    1. Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. The New England Journal of Medicine. 1996;334(8):488–493. - PubMed
    1. Major P, Lortholary A, Hon J, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. Journal of Clinical Oncology. 2001;19(2):558–567. - PubMed

Publication types

MeSH terms